Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancer

BACKGROUND: The programmed death-ligand 1 (PD-L1) 22C3 assay is one of the approved companion diagnostic assays for receiving anti-programmed cell death ligand 1 (PD-L1) therapy. Our study evaluated the performance of E1L3N and 22C3 antibodies in estimating PD-L1 expression in non-small cell lung ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Lianxi, Zeng, Liang, Yan, Huan, Xu, Qinqin, Xia, Qing, Lei, Jian, Chen, Xiaoyan, Hu, Xiaoping, Wang, Zhan, Liu, Hong, Yang, Nong, Zhang, Yongchang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626637/
https://www.ncbi.nlm.nih.gov/pubmed/36352254
http://dx.doi.org/10.1038/s43856-022-00206-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626637/
https://www.ncbi.nlm.nih.gov/pubmed/36352254
http://dx.doi.org/10.1038/s43856-022-00206-4

Ejemplares similares